DGX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DGX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pretax income is the income that a company earns before paying income taxes. Quest Diagnostics's pretax income for the three months ended in Sep. 2024 was $296 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $1,113 Mil. Quest Diagnostics's pretax margin was 11.90%.
During the past 13 years, Quest Diagnostics's highest Pretax Margin was 24.09%. The lowest was 11.07%. And the median was 13.93%.
The historical data trend for Quest Diagnostics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Pre-Tax Income | Get a 7-Day Free Trial | 1,076.00 | 1,884.00 | 2,599.00 | 1,235.00 | 1,130.00 |
Quest Diagnostics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Pre-Tax Income | Get a 7-Day Free Trial | 299.00 | 237.00 | 266.00 | 314.00 | 296.00 |
For the Diagnostics & Research subindustry, Quest Diagnostics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's Pre-Tax Income falls into.
This is the income that a company earns before paying income taxes.
Quest Diagnostics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pretax Income | = | Operating Income | + | Non Operating Income | + | Interest Expense | + | Interest Income | + | Other |
= | 1262 | + | 20 | + | -163 | + | 11 | + | 0 | |
= | 1,130 |
Quest Diagnostics's Pretax Income for the quarter that ended in Sep. 2024 is calculated as
Pretax Income | = | Operating Income | + | Non Operating Income | + | Interest Expense | + | Interest Income | + | Other |
= | 330 | + | 15 | + | -58 | + | 9 | + | 0 | |
= | 296 |
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,113 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics (NYSE:DGX) Pre-Tax Income Explanation
Quest Diagnostics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
Pretax Margin | = | Pretax Income | / | Revenue |
= | 296 | / | 2488 | |
= | 11.90% |
During the past 13 years, Quest Diagnostics's highest Pretax Margin was 24.09%. The lowest was 11.07%. And the median was 13.93%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Quest Diagnostics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael E Prevoznik | officer: Corp VP, Legal & Compliance | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Catherine T. Doherty | officer: SVP, Physician Services Bus. | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Michael J Deppe | officer: VP, Corp. Controller & CAO | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS, SECAUCUS NJ 07094 |
Karthik Kuppusamy | officer: SVP, Clinical Solutions | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
Mark E Delaney | officer: SVP & Chief Commercial Officer | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
Vicky B Gregg | director | 1 CAMERON HILL CIRCLE, CHATTANOOGA TN 37402 |
Luis Diaz | director | C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02138 |
Timothy M Ring | director | C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974 |
Mark A Gardner | officer: SVP of Molecular Gen & Oncol | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
Patrick Plewman | officer: SVP for Diagnostic Services | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
Samer Abdul Samad | officer: Executive Vice President & CFO | 5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
Stephen H Rusckowski | director, officer: President and CEO | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Tracey Doi | director | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Gail R Wilensky | director | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Mark Guinan | officer: Senior Vice President & CFO | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
From GuruFocus
By ACCESSWIRE • 10-10-2024
By GuruFocus News • 10-23-2024
By ACCESSWIRE • 09-26-2024
By ACCESSWIRE • 11-07-2024
By ACCESSWIRE • 11-26-2024
By ACCESSWIRE • 10-29-2024
By GuruFocus News • 10-22-2024
By ACCESSWIRE • 12-04-2024
By PRNewswire • 10-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.